Rolle der Immuntherapie bei gynäkologischen Tumoren

Wann, wo und wie einsetzen?

This is a preview of subscription content, access via your institution.

Abb 1

Literatur

  1. 1.

    Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54

  2. 2.

    Pardoll DM et al. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):252

  3. 3.

    Pinto MP et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10-17

  4. 4.

    Paijens ST et al. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020; https://doi.org/10.1038/s41423-020-00565-9

  5. 5.

    Mezache L et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28:1594-602

  6. 6.

    Liu YL et al. Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers. Curr Oncol Rep. 2018;20(12):94

  7. 7.

    Qin Y et al. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulator. Front Immunol. 2017;16;8:689

  8. 8.

    Chung HC et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2018;37(17):1470-8

  9. 9.

    Frenel JS et al. Safety and efficacy of pembrolizumab in advanced, programmed death Ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035-41

  10. 10.

    Naumann RW et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol. 2019;37(31):2825-34

  11. 11.

    Naumann RW et al. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358. Ann Oncol. 2019;30(suppl_5): v851-v934

  12. 12.

    Migden MR et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379(4):341-51

  13. 13.

    Deshpande M et al. Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability. Cancers (Basel). 2020;12(11):3319

  14. 14.

    Howitt BE et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319-23

  15. 15.

    Le et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11-9

  16. 16.

    Marabelle A et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10

  17. 17.

    Green AK et al. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. Am Soc Clin Oncol Educ Book. 2020;40:1-7

  18. 18.

    Oaknin A et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. Ann Oncol. 2020;31(suppl_4):S1142-S1215

  19. 19.

    Oaknin A et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol. 2020;6(11):1766-72

  20. 20.

    Kandalaft LA et al. Immune Therapy Opportunities in Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2020;40:1-13

  21. 21.

    Omatsu K et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial). Ann Oncol. 2020;31(suppl_4): S551-S589

  22. 22.

    Pujade-Lauraine et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. 2019 Gynecologic Oncol. 2019;154(1):21-2.

  23. 23.

    Pal T et al. Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology. Clin Cancer Res. 2008;14(21):6847-54

  24. 24.

    Zamarin D et al. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol. 2020;38(16):1814-23

  25. 25.

    Lee EK and Konstantinopoulos PA. Olaparib induced activation of Stimulator of Interferon Genes (STING) pathway accompanied by increased expression of Interferon-beta, PD-L1 and CXCL10. Trends Cancer. 2019;5:524-8

  26. 26.

    Ding L et al. PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer. Cell Rep. 2018;25(11):2972-80

  27. 27.

    Shen J et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79(2):311-9

  28. 28.

    Wang Z et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019; 9(1):1853

  29. 29.

    Konstantinopoulos PA et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;13;5(8):1141-9

  30. 30.

    Drew Y et al. Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2019;30(suppl 5):v475-v532

  31. 31.

    Drew Y et al. Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC). Ann Oncol. 2020;31(suppl_4):S551-S589

  32. 32.

    Moore K et al. Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Ann Oncol. 2020;31(suppl 4): S1142-S1215

  33. 33.

    Howitt BE et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD 1 and PD-L1. JAMA Oncol. 2015;1(9):1319

  34. 34.

    Makker V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711-8

  35. 35.

    Stevanović S et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543

  36. 36.

    Stevanocvić S et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally-induced epithelial cancer. Science. 201;356(6334):200-5

  37. 37.

    Zhu X et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8(38):64607-21

  38. 38.

    Lynam S et al. Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clin Obstet Gynecol. 2020;63(1):48-63

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Priv.-Doz. Dr. med. Antonia Busse.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Busse, A., Letsch, A. Wann, wo und wie einsetzen?. Im Fokus Onkologie 24, 14–18 (2021). https://doi.org/10.1007/s15015-021-3387-5

Download citation